A research study published in "The New England Journal of Medicine" describes a significant mortality response to the immunotherapy Atezolizumab used in conjunction with the chemotherapy nab-paclitaxel for a type of untreatable Breast cancer (Triple-negative) when the tumors also display programmed death ligand 1 (PD-L1) expression.
